SYS6043

Conjupro Biotherapeutics, Inc. · Phase 1 active Small molecule

At a glance

Generic name	SYS6043
Sponsor	Conjupro Biotherapeutics, Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors (PHASE1)
Phase 1/II Clinical Study of SYS6043 in the Treatment of Advanced/Metastatic Solid Tumors (PHASE1, PHASE2)
A Study of Sirolimus (Albumin-Bound) in Combination With Different ADCs Treatment of Advanced Solid Tumors (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

SYS6043 CI brief — competitive landscape report
SYS6043 updates RSS · CI watch RSS
Conjupro Biotherapeutics, Inc. portfolio CI